erlotinib has been researched along with apixaban in 2 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (apixaban) | Trials (apixaban) | Recent Studies (post-2010) (apixaban) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 2,405 | 255 | 2,250 |
| Protein | Taxonomy | erlotinib (IC50) | apixaban (IC50) |
|---|---|---|---|
| Coagulation factor X | Homo sapiens (human) | 0.22 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
2 other study(ies) available for erlotinib and apixaban
| Article | Year |
|---|---|
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |